JOSHUA MAKOWER

CIK 1235952 · last filed 2022-10-14

JOSHUA MAKOWER is a corporate insider who has filed 46 SEC Form 4 insider transactions across 18 companies since 2016. The most recent filing, for EAR, was dated Oct 14, 2022. Across all open-market trades the lifetime net is +$218.0M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $678.5M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$678.52M

Companies

18

Total Filings

46

Lifetime Open-Market Net

$218.01M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Eargo, Inc. (EAR) Delisted Director 1,500 $2.57 $3.9K $5.60M 5 2022-10-14
NeueHealth, Inc. (BHG) Delisted 10%+ Owner 278,608 $16.35 $4.56M $35.00M 1 2021-06-30
GLUE 10%+ Owner 5,973,296 $22.04 $131.65M $19.95M 1 2021-06-30
Desktop Metal, Inc. (DM) Delisted 10%+ Owner 228 $4.96 $1.1K $0 1 2021-06-10
MRKR 10%+ Owner 1,071,428 $1.18 $1.26M $10.00M 1 2021-03-18
Regulus Therapeutics Inc. (RGLS) Delisted 10%+ Owner 645,106 $8.16 $5.26M $3.96M 3 2020-12-07
Metacrine, Inc. (MTCR) Delisted 10%+ Owner 1,958,333 $0.49 $969.2K $10.00M 1 2020-09-22
Inozyme Pharma, Inc. (INZY) Delisted 10%+ Owner 2,000,533 $4.00 $8.00M $4.00M 1 2020-07-28
GENOCEA BIOSCIENCES, INC. (GNCA) Delisted 10%+ Owner 10,376,936 $0.00 $6.2K $21.78M 3 2020-07-28
NKTX 10%+ Owner 522,639 $2.22 $1.16M $12.00M 1 2020-07-16
Akouos, Inc. (AKUS) Delisted 10%+ Owner 513,758 $13.29 $6.83M $10.00M 1 2020-07-01
AVEO PHARMACEUTICALS, INC. (AVEO) Delisted 10%+ Owner 3,952,958 $15.00 $59.29M $24.62M 16 2020-06-22
TRVI 10%+ Owner 5,938,562 $18.43 $109.45M $25.00M 2 2020-04-13
ARDX 10%+ Owner 3,082,186 $5.08 $15.67M $23.33M 4 2019-12-09
MIRM 10%+ Owner 3,736,243 $112.23 $419.32M $6.75M 1 2019-07-24
Oruka Therapeutics, Inc. (ABIO) Delisted 10%+ Owner 0 $28.80 $0 -$731.3K 1 2018-02-27
Cascadian Therapeutics, Inc. (CASC) Delisted 10%+ Owner 10,882,574 $0 1 2018-02-22
Achaogen, Inc. (AKAO) Delisted 10%+ Owner 5,215,128 $6.75M 1 2016-12-19

Recent Filings

46 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-10-14 Eargo, Inc. (EAR) Delisted Grant (A) $0 EDGAR
2022-08-25 Eargo, Inc. (EAR) Delisted Grant (A) $0 EDGAR
2021-06-30 NeueHealth, Inc. (BHG) Delisted Mixed +135,584,859 $35.00M EDGAR
2021-06-30 GLUE Mixed +7,692,298 $19.95M EDGAR
2021-06-10 Desktop Metal, Inc. (DM) Delisted Other (J) −8,997,715 $0 EDGAR
2021-05-26 Eargo, Inc. (EAR) Delisted Other (J) −1,999,492 $0 EDGAR
2021-03-18 MRKR Buy (P) +5,714,285 $10.00M EDGAR
2020-12-07 Regulus Therapeutics Inc. (RGLS) Delisted Buy (P) +4,398,602 $2.74M EDGAR
2020-10-22 Eargo, Inc. (EAR) Delisted Mixed +6,520,017 $5.60M EDGAR
2020-10-19 Eargo, Inc. (EAR) Delisted Grant (A) $0 EDGAR
Showing 110 of 46
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.